|
| | Publication Year | Title | Author(s) |
| 1 | 9-Dec-2013 | Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. | Butts, Charles; Socinski, Mark A; Mitchell, Paul L R ; Thatcher, Nick; Havel, Libor; Krzakowski, Maciej; Nawrocki, Sergiusz; Ciuleanu, Tudor-Eliade; Bosquée, Lionel; Trigo, José Manuel; Spira, Alexander; Tremblay, Lise; Nyman, Jan; Ramlau, Rodryg; Wickart-Johansson, Gun; Ellis, Peter; Gladkov, Oleg; Pereira, José Rodrigues; Eberhardt, Wilfried Ernst Erich; Helwig, Christoph; Schröder, Andreas; Shepherd, Frances A |
| 2 | 18-Nov-2013 | Lung cancer in Victoria: are we making progress? | Mitchell, Paul L R ; Thursfield, Vicky J; Ball, David L; Richardson, Gary E; Irving, Louis B; Torn-Broers, Yvonne; Giles, Graham G; Wright, Gavin M |
| 3 | 16-Oct-2013 | Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer. | Liew, Mun Sem; Sia, Joseph; Starmans, Maud H W; Tafreshi, Ali; Harris, Sam; Feigen, Malcolm; White, Shane C; Zimet, Allan; Lambin, Philippe; Boutros, Paul C; Mitchell, Paul L R ; John, Thomas |
| 4 | 23-Jul-2013 | The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer. | John, Thomas ; Starmans, Maud H W; Chen, Yao-Tseng; Russell, Prudence A; Barnett, Stephen A ; White, Shane C; Mitchell, Paul L R ; Walkiewicz, Marzena; Azad, Arun A; Lambin, Philippe; Tsao, Ming-Sound; Deb, Siddhartha; Altorki, Nasser; Wright, Gavin; Knight, Simon R ; Boutros, Paul C; Cebon, Jonathan S |
| 5 | 6-Jun-2012 | Pulmonary metastases: a rare manifestation of the most common cancer. | Arulananda, Surein; Liew, Mun Sem; Battye, Shane; McDonald, Christine F ; Mitchell, Paul L R |
| 6 | 1-Oct-2011 | Bronchoepidural Fistula in a man with actinomycosis complicated non-small cell lung cancer. | Sem Liew, Mun; Arulananda, Surein; Seow, James; Mitchell, Paul L R ; John, Thomas |
| 7 | 23-May-2011 | Randomized phase 2 sequencing and pharmacokinetic study of gemcitabine and oxaliplatin in advanced non-small cell lung cancer. | Mitchell, Paul L R ; Broad, Adam; Rosenthal, Mark A; Galettis, Peter; Abraham, Rick; Burns, Ivon; Clarke, Stephen; Milner, Alvin; Diiulio, Juliana; Links, Matthew |
| 8 | 24-Dec-2009 | Neurolymphomatosis: diagnosis, management, and outcomes in patients treated with rituximab. | Gan, Hui K ; Azad, Arun A; Cher, Lawrence M ; Mitchell, Paul L R |
| 9 | 17-Nov-2009 | High impact of 18F-FDG-PET on management and prognostic stratification of newly diagnosed small cell lung cancer. | Azad, Arun A; Chionh, Fiona; Scott, Andrew M ; Lee, Szeting T; Berlangieri, Salvatore U ; White, Shane C; Mitchell, Paul L R |
| 10 | 28-Mar-2009 | Prognostic value of 18F-FDG PET/CT in patients with malignant pleural mesothelioma. | Lee, S T; Ghanem, M; Herbertson, R A; Berlangieri, Salvatore U ; Byrne, Amanda J; Tabone, K; Mitchell, Paul L R ; Knight, Simon R ; Feigen, Malcolm; Scott, Andrew M |
| 11 | 21-May-2007 | Prevalence of occult metastatic disease in patients undergoing 18F-FDG PET for primary diagnosis or staging of lung carcinoma and solitary pulmonary nodules. | Lee, S T; Berlangieri, Salvatore U ; Poon, A M T; Mitchell, Paul L R ; Pathmaraj, K ; Tabone, K; Byrne, Amanda J; O'Keefe, Graeme J; Knight, Simon R ; Clarke, C Peter; Scott, Andrew M |
| 12 | 1-Jul-2006 | Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. | Mitchell, Paul L R ; Goldstein, David B; Michael, Michael; Beale, Philip; Friedlander, Michael; Zalcberg, John; White, Shane C; Thomson, Jacquelyn A; Clarke, Stephen |
| 13 | 1-Feb-2006 | Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. | Loveland, Bruce E; Zhao, Anne; White, Shane C; Gan, Hui K ; Hamilton, Kate ; Xing, Pei-Xiang; Pietersz, Geoffrey A; Apostolopoulos, Vasso; Vaughan, Hilary A; Karanikas, Vaios; Kyriakou, Peter; McKenzie, Ian F C; Mitchell, Paul L R |
| 14 | 19-Nov-2005 | A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumors. | Gan, Hui K ; Mitchell, Paul L R ; Galettis, Peter; Davis, Ian D; Cebon, Jonathan S ; de Souza, Paul; Links, Matthew |
| 15 | 5-May-2005 | Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small cell lung cancer. | Yap, Kelvin K; Byrne, Amanda J; Berlangieri, Salvatore U ; Poon, Aurora M T ; Mitchell, Paul L R ; Knight, Simon R ; Clarke, Peter C; Harris, Anthony H; Tauro, Andrew; Rowe, Christopher C ; Scott, Andrew M |
| 16 | 1-Jul-2004 | Positron emission tomography scanning in the assessment of patients with lymphoma. | Foo, S S; Mitchell, Paul L R ; Berlangieri, Salvatore U ; Smith, C L; Scott, Andrew M |
| 17 | 1-May-2003 | A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. | Scott, Andrew M ; Wiseman, Greg; Welt, Sydney; Adjei, Alex; Lee, Fook-Thean; Hopkins, Wendie; Divgi, Chaitan R; Hanson, Lorelei H; Mitchell, Paul L R ; Gansen, Denise N; Larson, Steven M; Ingle, James N; Hoffman, Eric W; Tanswell, Paul; Ritter, Gerd; Cohen, Leonard S; Bette, Peter; Arvay, Lisa; Amelsberg, Andree; Vlock, Dan; Rettig, Wolfgang J; Old, Lloyd J |
| 18 | 1-Aug-1999 | KRN8602 (MX2-hydrochloride): an active new agent for the treatment of recurrent high-grade glioma. | Clarke, K; Basser, R L; Underhill, C; Mitchell, Paul L R ; Bartlett, John; Cher, Lawrence M ; Findlay, M; Dalley, D; Pell, M; Byrne, M; Geldard, H; Hill, J S; Maher, D; Fox, R M; Green, M D; Kaye, A H |
Loading...
2
0
20
0
false